Aspen Aerogels (ASPN) Cash & Equivalents (2013 - 2026)

Aspen Aerogels has reported Cash & Equivalents for 14 years, with the latest figure at $173.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 9.45% year-over-year to $173.9 million; the trailing twelve-month figure through Mar 2026 stood at $173.9 million (down 9.45% YoY), and the FY2025 full-year result was $156.9 million, down 28.99% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $173.9 million, up from $156.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $281.3 million in Q4 2022, with the low at $91.4 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $158.6 million across 5 years, with a median of $156.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 1091.57% — and 2024, when it plunged 51.08%.
• Aspen Aerogels' Cash & Equivalents stood at $281.3 million in 2022, then plunged by 50.34% to $139.7 million in 2023, then soared by 58.09% to $220.9 million in 2024, then dropped by 28.99% to $156.9 million in 2025, then gained by 10.87% to $173.9 million in 2026.
• The last three Cash & Equivalents figures came in at $173.9 million (Q1 2026), $156.9 million (Q4 2025), and $150.7 million (Q3 2025), per Business Quant data.